Key clinical point: A new meta-analysis – the largest ever – provides further evidence that statins protect against development of hepatocellular carcinoma.

Major finding: The risk of new-onset hepatocellular carcinoma was 43% lower in statin users than nonusers.

Study details: This was a meta-analysis of 20 published statin/hepatocellular carcinoma studies including more than 24,000 cases of new-onset hepatocellular carcinoma.

Disclosures: The presenter reported having no financial conflicts regarding his study, which was conducted free of commercial support.